Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
10x Genomics downgraded to Sell from Neutral at Goldman Sachs » 04:37
08/18/22
08/18
04:37
08/18/22
04:37
TXG

10x Genomics

$42.89 /

-3.475 (-7.49%)

Goldman Sachs analyst…

Goldman Sachs analyst Matthew Sykes downgraded 10x Genomics to Sell from Neutral with a price target of $35, down from $55, which represents 18% downside from current levels. The analyst expects a "materially slower cadence" to the company's sales growth rate in 2023 and 2024 versus consensus as it transitions to a multi-market, multi-product company. The growth rate for 10x's single cell analysis business is below what analysts have modeled over the next few years as its penetration into the academic market "has hit a ceiling amongst the high utilization, core lab customers," Sykes tells investors in a research note. He adds that the company's spatial and in situ offerings "are not yet of the size to help offset the deceleration in their core business."

ShowHide Related Items >><<
TXG 10x Genomics
$42.89 /

-3.475 (-7.49%)

TXG 10x Genomics
$42.89 /

-3.475 (-7.49%)

08/11/22 Piper Sandler
Illumina miss 'surprising' given backlog, says Piper Sandler
08/10/22 Morgan Stanley
10x Genomics price target lowered to $70 from $100 at Morgan Stanley
08/09/22 Cowen
10x Genomics price target raised to $55 from $50 at Cowen
08/09/22 Citi
10x Genomics price target lowered to $65 from $100 at Citi
TXG 10x Genomics
$42.89 /

-3.475 (-7.49%)

TXG 10x Genomics
$42.89 /

-3.475 (-7.49%)

Recommendations
Illumina miss 'surprising' given backlog, says Piper Sandler » 16:41
08/11/22
08/11
16:41
08/11/22
16:41
ILMN

Illumina

$227.64 /

+0.44 (+0.19%)

, PACB

Pacific Biosciences

$7.94 /

+0.245 (+3.18%)

, TXG

10x Genomics

$48.22 /

+1.27 (+2.71%)

Piper Sandler analyst…

Piper Sandler analyst David Westenberg notes that Illumina just reported revenues, earnings and guidance that came in "well below consensus," which he calls "surprising" given the company's "rich" backlog of NovaSeq instruments and consumables. The analyst, who sees the miss potentially signaling that new orders in excess of backlog filling slowed "dramatically," argues that "the silver lining, if any," is that most of the other single products genomics companies, such as Pacific Biosciences (PACB) and 10x Genomics (TXG), also noted transitory headwinds from the macro environment. Westenberg, who thinks Illumina continues to have a strong competitive position, has an Overweight rating on the shares, which are down $51.49, or 23%, to $175.95 in after-hours trading.

ShowHide Related Items >><<
TXG 10x Genomics
$48.22 /

+1.27 (+2.71%)

PACB Pacific Biosciences
$7.94 /

+0.245 (+3.18%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

07/14/22 Canaccord
Illumina merger challenge not reflection of merits, says Canaccord
07/13/22 Piper Sandler
Illumina uncertainty over Grail continues with ruling, says Piper Sandler
07/13/22 Barclays
Illumina downgraded to Underweight from Equal Weight at Barclays
07/08/22 Citi
Illumina price target lowered to $220 from $325 at Citi
PACB Pacific Biosciences
$7.94 /

+0.245 (+3.18%)

08/04/22 Canaccord
Pacific Biosciences price target lowered to $14 from $17 at Canaccord
05/15/22 Piper Sandler
Pacific Biosciences price target lowered to $6 from $13 at Piper Sandler
05/05/22 Cantor Fitzgerald
Pacific Biosciences price target lowered to $19 from $23 at Cantor Fitzgerald
03/01/22 Piper Sandler
Pacific Biosciences price target lowered to $13 from $20 at Piper Sandler
TXG 10x Genomics
$48.22 /

+1.27 (+2.71%)

08/10/22 Morgan Stanley
10x Genomics price target lowered to $70 from $100 at Morgan Stanley
08/09/22 Cowen
10x Genomics price target raised to $55 from $50 at Cowen
08/09/22 Citi
10x Genomics price target lowered to $65 from $100 at Citi
07/25/22 Canaccord
Canaccord starts 10x Genomics at Buy, sees multiple avenues for long-term growth
TXG 10x Genomics
$48.22 /

+1.27 (+2.71%)

PACB Pacific Biosciences
$7.94 /

+0.245 (+3.18%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

TXG 10x Genomics
$48.22 /

+1.27 (+2.71%)

PACB Pacific Biosciences
$7.94 /

+0.245 (+3.18%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

PACB Pacific Biosciences
$7.94 /

+0.245 (+3.18%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

Recommendations
10x Genomics price target lowered to $70 from $100 at Morgan Stanley » 08:45
08/10/22
08/10
08:45
08/10/22
08:45
TXG

10x Genomics

$44.88 /

+1.43 (+3.29%)

Morgan Stanley analyst…

Morgan Stanley analyst Tejas Savant lowered the firm's price target on 10x Genomics to $70 from $100 and keeps an Overweight rating on the shares after the company reported Q2 results in line with its preannouncement and cut guidance, which was "unsurprising" following the preliminary release. The meaningful outlook reset should be "a clearing event for the stock," said Savant, who likes the setup into 2023 and beyond with Fixed RNA Profiling and CytAssist seeing strong initial traction and Xenium on track for year-end.

ShowHide Related Items >><<
TXG 10x Genomics
$44.88 /

+1.43 (+3.29%)

TXG 10x Genomics
$44.88 /

+1.43 (+3.29%)

08/09/22 Cowen
10x Genomics price target raised to $55 from $50 at Cowen
08/09/22 Citi
10x Genomics price target lowered to $65 from $100 at Citi
07/25/22 Canaccord
Canaccord starts 10x Genomics at Buy, sees multiple avenues for long-term growth
07/25/22 Canaccord
10x Genomics initiated with a Buy at Canaccord
TXG 10x Genomics
$44.88 /

+1.43 (+3.29%)

TXG 10x Genomics
$44.88 /

+1.43 (+3.29%)

Recommendations
10x Genomics price target raised to $55 from $50 at Cowen » 07:35
08/09/22
08/09
07:35
08/09/22
07:35
TXG

10x Genomics

$43.45 /

+0.83 (+1.95%)

Cowen analyst Dan Brennan…

Cowen analyst Dan Brennan raised the firm's price target on 10x Genomics to $55 from $50 and keeps an Outperform rating on the shares. The analyst said preannouncing a 2Q miss the focus was on the extent of a 2022 guidance cut which looks reasonable and clarity on the issues where a recovery where visibility remains low.

ShowHide Related Items >><<
TXG 10x Genomics
$43.45 /

+0.83 (+1.95%)

TXG 10x Genomics
$43.45 /

+0.83 (+1.95%)

08/09/22 Citi
10x Genomics price target lowered to $65 from $100 at Citi
07/25/22 Canaccord
Canaccord starts 10x Genomics at Buy, sees multiple avenues for long-term growth
07/25/22 Canaccord
10x Genomics initiated with a Buy at Canaccord
07/15/22 Morgan Stanley
10x Genomics reset a 'clearing event,' says Morgan Stanley
TXG 10x Genomics
$43.45 /

+0.83 (+1.95%)

TXG 10x Genomics
$43.45 /

+0.83 (+1.95%)

Recommendations
10x Genomics price target lowered to $65 from $100 at Citi » 06:35
08/09/22
08/09
06:35
08/09/22
06:35
TXG

10x Genomics

$43.45 /

+0.83 (+1.95%)

Citi analyst Patrick…

Citi analyst Patrick Donnelly lowered the firm's price target on 10x Genomics to $65 from $100 and keeps a Buy rating on the shares post the Q2 results. Particular focus was the lowered fiscal 2022 revenue guidance, which management attributed to China COVID lockdowns, currency headwinds, and the post-pandemic growth ramp tracking below expectations, Donnelly tells investors in a research note. The analyst believes the guidance reduction was broadly expected, but views the updated guidance cut of $100M as worse than anticipated.

ShowHide Related Items >><<
TXG 10x Genomics
$43.45 /

+0.83 (+1.95%)

TXG 10x Genomics
$43.45 /

+0.83 (+1.95%)

07/25/22 Canaccord
Canaccord starts 10x Genomics at Buy, sees multiple avenues for long-term growth
07/25/22 Canaccord
10x Genomics initiated with a Buy at Canaccord
07/15/22 Morgan Stanley
10x Genomics reset a 'clearing event,' says Morgan Stanley
07/15/22 BofA
BofA sees 'no quick fix' for 10x Genomics, downgrades to Underperform
TXG 10x Genomics
$43.45 /

+0.83 (+1.95%)

TXG 10x Genomics
$43.45 /

+0.83 (+1.95%)

Earnings
10x Genomics updated FY22 revenue view to $500M-$520M, consensus $571.06M » 16:12
08/08/22
08/08
16:12
08/08/22
16:12
TXG

10x Genomics

$43.50 /

+0.88 (+2.06%)

10x Genomics is updating…

10x Genomics is updating its outlook for the FY22. The company now expects revenue to be in the range of $500M-$520M, representing 2% to 6% growth over FY21.

ShowHide Related Items >><<
TXG 10x Genomics
$43.50 /

+0.88 (+2.06%)

TXG 10x Genomics
$43.50 /

+0.88 (+2.06%)

07/25/22 Canaccord
Canaccord starts 10x Genomics at Buy, sees multiple avenues for long-term growth
07/25/22 Canaccord
10x Genomics initiated with a Buy at Canaccord
07/15/22 Morgan Stanley
10x Genomics reset a 'clearing event,' says Morgan Stanley
07/15/22 BofA
BofA sees 'no quick fix' for 10x Genomics, downgrades to Underperform
TXG 10x Genomics
$43.50 /

+0.88 (+2.06%)

TXG 10x Genomics
$43.50 /

+0.88 (+2.06%)

Earnings
10x Genomics reports Q2 EPS (57c), consensus (39c) » 16:10
08/08/22
08/08
16:10
08/08/22
16:10
TXG

10x Genomics

$43.51 /

+0.89 (+2.09%)

Reports Q2 revenue…

Reports Q2 revenue $114.6M, consensus $117.19M. Cash and cash equivalents and marketable securities were $499.7M as of June 30. "Our results this quarter fell short of our expectations as we navigated some macro headwinds, particularly outside of the United States," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "Our topline growth this year will be slower than our previous expectations, but we firmly believe the underlying opportunity for our single cell and spatial technologies is as strong as ever. We are driving our innovation engine and building on our broad commercial reach so we can deliver on the full potential of this tremendous opportunity."

ShowHide Related Items >><<
TXG 10x Genomics
$43.51 /

+0.89 (+2.09%)

TXG 10x Genomics
$43.51 /

+0.89 (+2.09%)

07/25/22 Canaccord
Canaccord starts 10x Genomics at Buy, sees multiple avenues for long-term growth
07/25/22 Canaccord
10x Genomics initiated with a Buy at Canaccord
07/15/22 Morgan Stanley
10x Genomics reset a 'clearing event,' says Morgan Stanley
07/15/22 BofA
BofA sees 'no quick fix' for 10x Genomics, downgrades to Underperform
TXG 10x Genomics
$43.51 /

+0.89 (+2.09%)

TXG 10x Genomics
$43.51 /

+0.89 (+2.09%)

Hot Stocks
Singular Genomics appoints Ropp as Chief Commercial Officer » 07:48
08/02/22
08/02
07:48
08/02/22
07:48
OMIC

Singular Genomics

$3.82 /

+ (+0.00%)

, TXG

10x Genomics

$39.82 /

-0.335 (-0.83%)

Singular Genomics Systems…

Singular Genomics Systems (OMIC) announced the appointment of Sam Ropp, Ph.D., as Chief Commercial Officer. In this role, Dr. Ropp will oversee the company's commercial function, including commercialization of the G4 Sequencing Platform. He will report to Drew Spaventa, Chief Executive Officer and Founder of Singular Genomics. The company also announced the appointment of Jeff Bullard as Head of Sales for North America. Ropp joins Singular from 10x Genomics (TXG), most recently serving as Senior Vice President of Global Sales. Bullard joins Singular from 10x Genomics, where he most recently served as the Senior Director of Sales-Americas.

ShowHide Related Items >><<
TXG 10x Genomics
$39.82 /

-0.335 (-0.83%)

OMIC Singular Genomics
$3.82 /

+ (+0.00%)

OMIC Singular Genomics
$3.82 /

+ (+0.00%)

01/07/22 BofA
Singular Genomics upgraded to Buy from Neutral at BofA
01/07/22 BofA
Singular Genomics upgraded to Buy from Neutral at BofA
01/06/22 UBS
Singular Genomics price target lowered to $25 from $32 at UBS
10/14/21 Cowen
Singular Genomics coverage transferred at Cowen
TXG 10x Genomics
$39.82 /

-0.335 (-0.83%)

07/25/22 Canaccord
Canaccord starts 10x Genomics at Buy, sees multiple avenues for long-term growth
07/25/22 Canaccord
10x Genomics initiated with a Buy at Canaccord
07/15/22 Morgan Stanley
10x Genomics reset a 'clearing event,' says Morgan Stanley
07/15/22 BofA
BofA sees 'no quick fix' for 10x Genomics, downgrades to Underperform
TXG 10x Genomics
$39.82 /

-0.335 (-0.83%)

OMIC Singular Genomics
$3.82 /

+ (+0.00%)

TXG 10x Genomics
$39.82 /

-0.335 (-0.83%)

OMIC Singular Genomics
$3.82 /

+ (+0.00%)

On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 10:00
07/25/22
07/25
10:00
07/25/22
10:00
ATVI

Activision Blizzard

$79.53 /

+0.26 (+0.33%)

, MSFT

Microsoft

$258.50 /

-1.8 (-0.69%)

, TRV

Travelers

$159.00 /

+2.58 (+1.65%)

, AN

AutoNation

$120.60 /

+3.49 (+2.98%)

, CMCSA

Comcast

$42.77 /

+0.15 (+0.35%)

, CMCSK

Comcast

$58.00 /

+ (+0.00%)

, DIS

Disney

$102.76 /

+0.05 (+0.05%)

, AMZN

Amazon.com

$123.03 /

+0.57 (+0.47%)

, NFLX

Netflix

$223.37 /

+2.85 (+1.29%)

, SIVB

SVB Financial

$377.90 /

+16.43 (+4.55%)

, SNAP

Snap

$9.99 /

+0.035 (+0.35%)

, UAL

United Airlines

$36.00 /

-0.31 (-0.85%)

, TWLO

Twilio

$86.97 /

-0.35 (-0.40%)

, PEGA

Pegasystems

$50.05 /

-0.01 (-0.02%)

, TWOU

2U

$9.99 /

-0.71 (-6.64%)

, LRCX

Lam Research

$454.14 /

-9.39 (-2.03%)

, IDCC

InterDigital

$61.23 /

-1.66 (-2.64%)

, IE

Ivanhoe Electric

$8.77 /

+0.37 (+4.40%)

, TXG

10x Genomics

$35.33 /

+0.24 (+0.68%)

, BXC

BlueLinx

$75.46 /

-0.22 (-0.29%)

, IART

Integra LifeSciences

$54.42 /

+ (+0.00%)

, LPRO

Open Lending

$9.67 /

-1.385 (-12.53%)

, WWE

WWE

$70.25 /

+3.78 (+5.69%)

Institutional investors…

ShowHide Related Items >><<
WWE WWE
$70.25 /

+3.78 (+5.69%)

UAL United Airlines
$36.00 /

-0.31 (-0.85%)

TXG 10x Genomics
$35.33 /

+0.24 (+0.68%)

TWOU 2U
$9.99 /

-0.71 (-6.64%)

TWLO Twilio
$86.97 /

-0.35 (-0.40%)

TRV Travelers
$159.00 /

+2.58 (+1.65%)

SNAP Snap
$9.99 /

+0.035 (+0.35%)

SIVB SVB Financial
$377.90 /

+16.43 (+4.55%)

PEGA Pegasystems
$50.05 /

-0.01 (-0.02%)

NFLX Netflix
$223.37 /

+2.85 (+1.29%)

MSFT Microsoft
$258.50 /

-1.8 (-0.69%)

LRCX Lam Research
$454.14 /

-9.39 (-2.03%)

IDCC InterDigital
$61.23 /

-1.66 (-2.64%)

IART Integra LifeSciences
$54.42 /

+ (+0.00%)

DIS Disney
$102.76 /

+0.05 (+0.05%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$42.77 /

+0.15 (+0.35%)

BXC BlueLinx
$75.46 /

-0.22 (-0.29%)

ATVI Activision Blizzard
$79.53 /

+0.26 (+0.33%)

AN AutoNation
$120.60 /

+3.49 (+2.98%)

AMZN Amazon.com
$123.03 /

+0.57 (+0.47%)

ATVI Activision Blizzard
$79.53 /

+0.26 (+0.33%)

07/25/22 MoffettNathanson
Activision Blizzard upgraded to Outperform at MoffettNathanson
05/31/22 Benchmark
Marcus, Imax, WWE added to entertainment top ideas list at Benchmark
05/06/22 Benchmark
Playstudios could still be target as industry consolidates, says Benchmark
04/25/22 Benchmark
Activision results for Blizzard 'somewhat shocking,' says Benchmark
MSFT Microsoft
$258.50 /

-1.8 (-0.69%)

07/25/22 Wells Fargo
Microsoft price target lowered to $350 from $400 at Wells Fargo
07/22/22 Cowen
Microsoft price target lowered to $330 from $360 at Cowen
07/20/22 BofA
Arista double downgraded to Underperform at BofA on upcoming deterioration
TRV Travelers
$159.00 /

+2.58 (+1.65%)

07/25/22 Raymond James
Travelers upgraded to Strong Buy from Market Perform at Raymond James
07/25/22 Raymond James
Travelers upgraded to Strong Buy from Market Perform at Raymond James
07/22/22 RBC Capital
Travelers price target lowered to $165 from $183 at RBC Capital
07/22/22 Barclays
Travelers price target lowered to $165 from $177 at Barclays
AN AutoNation
$120.60 /

+3.49 (+2.98%)

07/25/22 Seaport Global
AutoNation upgraded to Buy from Neutral at Seaport Global
07/22/22 Guggenheim
AutoNation price target raised to $213 from $205 at Guggenheim
07/15/22 JPMorgan
AutoNation price target lowered to $135 from $150 at JPMorgan
07/14/22 Morgan Stanley
AutoNation price target lowered to $104 from $107 at Morgan Stanley
CMCSA Comcast
$42.77 /

+0.15 (+0.35%)

07/25/22 Loop Capital
Loop Capital upgrades WWE to Buy on rising likelihood of company sale
07/20/22 KeyBanc
Disney price target lowered to $131 from $151 at KeyBanc
07/14/22 Stephens
Stephens says Netflix choice may leave 'no economics' for Trade Desk, Magnite
07/05/22 Vertical Group
Comcast downgraded to Mixed from Positive at Vertical Group
CMCSK Comcast
$58.00 /

+ (+0.00%)

05/23/22 Raymond James
Electronic Arts moves 'somewhat unexpected,' says Raymond James
04/14/22 Oppenheimer
Comcast price target lowered to $60 from $75 at Oppenheimer
03/23/22 Craig-Hallum
ComScore poised for share gains in local measurement, says Craig-Hallum
DIS Disney
$102.76 /

+0.05 (+0.05%)

07/25/22 Wells Fargo
Disney price target lowered to $130 from $153 at Wells Fargo
07/14/22 Barclays
Disney price target lowered to $120 from $130 at Barclays
AMZN Amazon.com
$123.03 /

+0.57 (+0.47%)

07/25/22 MKM Partners
Amazon.com price target lowered to $165 from $180 at MKM Partners
07/25/22 Truist
1Life Healthcare downgraded to Hold from Buy at Truist
07/25/22 Oppenheimer
Amazon.com price target lowered to $160 from $175 at Oppenheimer
NFLX Netflix
$223.37 /

+2.85 (+1.29%)

07/20/22 Oppenheimer
Netflix subscriber beat unlikely to alleviate concerns, says Oppenheimer
07/20/22 Evercore ISI
Evercore says market will need to see progress from Netflix for premium multiple
07/20/22 Morgan Stanley
Netflix price target raised to $230 from $220 at Morgan Stanley
SIVB SVB Financial
$377.90 /

+16.43 (+4.55%)

07/25/22 Maxim
SVB Financial price target lowered to $900 from $1,100 at Maxim
07/25/22 Truist
SVB Financial price target lowered to $500 from $557 at Truist
07/25/22 Barclays
SVB Financial price target lowered to $638 from $789 at Barclays
07/25/22 Evercore ISI
SVB Financial upgraded to Outperform from In Line at Evercore ISI
SNAP Snap
$9.99 /

+0.035 (+0.35%)

07/25/22 Wolfe Research
Snap downgraded to Peer Perform from Outperform at Wolfe Research
07/25/22 Morgan Stanley
Snap downgraded to Underweight from Overweight at Morgan Stanley
07/22/22 Cowen
Snap price target lowered to $10 from $17 at Cowen
07/22/22 MKM Partners
Snap price target lowered to $17 from $26 at MKM Partners
UAL United Airlines
$36.00 /

-0.31 (-0.85%)

07/25/22 Susquehanna
Susquehanna downgrades United Airlines with FY23 estimates not fully derisked
07/25/22 Citi
United Airlines price target lowered to $56 from $71 at Citi
07/25/22 Susquehanna
United Airlines downgraded to Neutral from Positive at Susquehanna
07/22/22 Cowen
United Airlines price target lowered to $75 from $86.50 at Cowen
TWLO Twilio
$86.97 /

-0.35 (-0.40%)

07/25/22 Macquarie
Macquarie downgrades trio of software names on recession risk
07/25/22 Macquarie
Twilio downgraded to Neutral from Outperform at Macquarie
07/22/22 Cowen
Twilio price target lowered to $150 from $250 at Cowen
07/19/22 Bernstein
Twilio initiated with a Market Perform at Bernstein
PEGA Pegasystems
$50.05 /

-0.01 (-0.02%)

07/25/22 Macquarie
Pegasystems downgraded to Neutral from Outperform at Macquarie
07/18/22 Barclays
Pegasystems price target lowered to $50 from $80 at Barclays
06/17/22 Loop Capital
Pegasystems price target lowered to $50 from $60 at Loop Capital
TWOU 2U
$9.99 /

-0.71 (-6.64%)

07/25/22 Macquarie
2U downgraded to Neutral from Outperform at Macquarie
06/29/22 William Blair
William Blair says 'would make sense' for Byju's to target 2U over Chegg
06/29/22 Piper Sandler
2U buyout at $15 may not be attractive to holders, says Piper Sandler
LRCX Lam Research
$454.14 /

-9.39 (-2.03%)

07/25/22 B. Riley
Lam Research price target lowered to $525 from $625 at B. Riley
07/25/22 Morgan Stanley
Lam Research price target lowered to $550 from $625 at Morgan Stanley
07/25/22 Barclays
Barclays downgrades Lam Research on semi 'head fake' rally
07/25/22 Barclays
Lam Research downgraded to Equal Weight from Overweight at Barclays
IDCC InterDigital
$61.23 /

-1.66 (-2.64%)

07/25/22 BofA
InterDigital initiated with an Underperform at BofA
08/03/21 Roth Capital
Court ruling sets tone for unlicensed Chinese OEMs in Europe, says Roth Capital
IE Ivanhoe Electric
$8.77 /

+0.37 (+4.40%)

07/25/22 Jefferies
Ivanhoe Electric initiated with a Buy at Jefferies
07/25/22 BMO Capital
Ivanhoe Electric initiated with an Outperform at BMO Capital
TXG 10x Genomics
$35.33 /

+0.24 (+0.68%)

07/25/22 Canaccord
Canaccord starts 10x Genomics at Buy, sees multiple avenues for long-term growth
07/25/22 Canaccord
10x Genomics initiated with a Buy at Canaccord
07/15/22 Morgan Stanley
10x Genomics reset a 'clearing event,' says Morgan Stanley
07/15/22 BofA
BofA sees 'no quick fix' for 10x Genomics, downgrades to Underperform
BXC BlueLinx
$75.46 /

-0.22 (-0.29%)

07/25/22 Seaport Global
BlueLinx initiated with a Buy at Seaport Global
02/24/22 Craig-Hallum
BlueLinx price target raised to $115 from $104 at Craig-Hallum
12/17/21
Fly Intel: Top five analyst initiations
12/17/21 DA Davidson
BlueLinx initiated with a Buy at DA Davidson
IART Integra LifeSciences
$54.42 /

+ (+0.00%)

07/25/22 Morgan Stanley
Integra LifeSciences initiated with an Equal Weight at Morgan Stanley
07/20/22 Truist
Integra LifeSciences price target lowered to $56 from $70 at Truist
05/17/22 Citi
Integra LifeSciences price target lowered to $67 from $70 at Citi
04/12/22 Truist
Truist starts six stocks in Medical Supplies and Devices, assumes eight others
LPRO Open Lending
$9.67 /

-1.385 (-12.53%)

07/25/22 Morgan Stanley
Open Lending downgraded to Underweight from Equal Weight at Morgan Stanley
07/13/22 JMP Securities
Open Lending price target lowered to $17 from $25 at JMP Securities
05/06/22 Deutsche Bank
Open Lending price target lowered to $18 from $25 at Deutsche Bank
05/06/22 Raymond James
Open Lending price target lowered to $22 from $30 at Raymond James
WWE WWE
$70.25 /

+3.78 (+5.69%)

07/25/22 MKM Partners
WWE price target raised to $79 from $70 at MKM Partners
07/25/22 Loop Capital
WWE upgraded to Buy from Hold at Loop Capital
07/25/22 Barclays
WWE price target raised to $61 from $57 at Barclays
WWE WWE
$70.25 /

+3.78 (+5.69%)

UAL United Airlines
$36.00 /

-0.31 (-0.85%)

TXG 10x Genomics
$35.33 /

+0.24 (+0.68%)

TWOU 2U
$9.99 /

-0.71 (-6.64%)

TWLO Twilio
$86.97 /

-0.35 (-0.40%)

TRV Travelers
$159.00 /

+2.58 (+1.65%)

SNAP Snap
$9.99 /

+0.035 (+0.35%)

SIVB SVB Financial
$377.90 /

+16.43 (+4.55%)

PEGA Pegasystems
$50.05 /

-0.01 (-0.02%)

NFLX Netflix
$223.37 /

+2.85 (+1.29%)

MSFT Microsoft
$258.50 /

-1.8 (-0.69%)

LRCX Lam Research
$454.14 /

-9.39 (-2.03%)

LPRO Open Lending
$9.67 /

-1.385 (-12.53%)

IDCC InterDigital
$61.23 /

-1.66 (-2.64%)

IART Integra LifeSciences
$54.42 /

+ (+0.00%)

DIS Disney
$102.76 /

+0.05 (+0.05%)

CMCSA Comcast
$42.77 /

+0.15 (+0.35%)

BXC BlueLinx
$75.46 /

-0.22 (-0.29%)

ATVI Activision Blizzard
$79.53 /

+0.26 (+0.33%)

AN AutoNation
$120.60 /

+3.49 (+2.98%)

AMZN Amazon.com
$123.03 /

+0.57 (+0.47%)

  • 28
    Jun
  • 10
    Aug
WWE WWE
$70.25 /

+3.78 (+5.69%)

UAL United Airlines
$36.00 /

-0.31 (-0.85%)

TWOU 2U
$9.99 /

-0.71 (-6.64%)

SNAP Snap
$9.99 /

+0.035 (+0.35%)

NFLX Netflix
$223.37 /

+2.85 (+1.29%)

MSFT Microsoft
$258.50 /

-1.8 (-0.69%)

LRCX Lam Research
$454.14 /

-9.39 (-2.03%)

DIS Disney
$102.76 /

+0.05 (+0.05%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$42.77 /

+0.15 (+0.35%)

ATVI Activision Blizzard
$79.53 /

+0.26 (+0.33%)

AMZN Amazon.com
$123.03 /

+0.57 (+0.47%)

WWE WWE
$70.25 /

+3.78 (+5.69%)

UAL United Airlines
$36.00 /

-0.31 (-0.85%)

TXG 10x Genomics
$35.33 /

+0.24 (+0.68%)

TWOU 2U
$9.99 /

-0.71 (-6.64%)

TWLO Twilio
$86.97 /

-0.35 (-0.40%)

TRV Travelers
$159.00 /

+2.58 (+1.65%)

SNAP Snap
$9.99 /

+0.035 (+0.35%)

SIVB SVB Financial
$377.90 /

+16.43 (+4.55%)

PEGA Pegasystems
$50.05 /

-0.01 (-0.02%)

NFLX Netflix
$223.37 /

+2.85 (+1.29%)

MSFT Microsoft
$258.50 /

-1.8 (-0.69%)

LRCX Lam Research
$454.14 /

-9.39 (-2.03%)

LPRO Open Lending
$9.67 /

-1.385 (-12.53%)

IE Ivanhoe Electric
$8.77 /

+0.37 (+4.40%)

IDCC InterDigital
$61.23 /

-1.66 (-2.64%)

DIS Disney
$102.76 /

+0.05 (+0.05%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$42.77 /

+0.15 (+0.35%)

BXC BlueLinx
$75.46 /

-0.22 (-0.29%)

ATVI Activision Blizzard
$79.53 /

+0.26 (+0.33%)

AN AutoNation
$120.60 /

+3.49 (+2.98%)

AMZN Amazon.com
$123.03 /

+0.57 (+0.47%)

UAL United Airlines
$36.00 /

-0.31 (-0.85%)

TWOU 2U
$9.99 /

-0.71 (-6.64%)

TWLO Twilio
$86.97 /

-0.35 (-0.40%)

SNAP Snap
$9.99 /

+0.035 (+0.35%)

SIVB SVB Financial
$377.90 /

+16.43 (+4.55%)

NFLX Netflix
$223.37 /

+2.85 (+1.29%)

MSFT Microsoft
$258.50 /

-1.8 (-0.69%)

LRCX Lam Research
$454.14 /

-9.39 (-2.03%)

DIS Disney
$102.76 /

+0.05 (+0.05%)

CMCSA Comcast
$42.77 /

+0.15 (+0.35%)

ATVI Activision Blizzard
$79.53 /

+0.26 (+0.33%)

AMZN Amazon.com
$123.03 /

+0.57 (+0.47%)

Initiation
Canaccord starts 10x Genomics at Buy, sees multiple avenues for long-term growth » 07:18
07/25/22
07/25
07:18
07/25/22
07:18
TXG

10x Genomics

$35.12 /

-1.59 (-4.33%)

As previously reported,…

As previously reported, Canaccord analyst Kyle Mikson initiated coverage of 10x Genomics with a Buy rating and $55 price target. 10x Genomics has historically show "impressive execution" in its single cell analysis business and he believes 10x will continue to generate solid growth in its single cell segment as its spatial biology and in situ businesses accelerate, Mikson tells investors. While acknowledging that the company may be adversely affected in a recessionary environment given 10x Genomics' academic-heavy customer base, he believes shares are "attractive at current levels" given that shares offer about 57% upside potential to his price target, Mikson added.

ShowHide Related Items >><<
TXG 10x Genomics
$35.12 /

-1.59 (-4.33%)

TXG 10x Genomics
$35.12 /

-1.59 (-4.33%)

07/25/22 Canaccord
10x Genomics initiated with a Buy at Canaccord
07/15/22 Morgan Stanley
10x Genomics reset a 'clearing event,' says Morgan Stanley
07/15/22 BofA
BofA sees 'no quick fix' for 10x Genomics, downgrades to Underperform
07/15/22 Cowen
10x Genomics price target lowered to $50 from $90 at Cowen
TXG 10x Genomics
$35.12 /

-1.59 (-4.33%)

TXG 10x Genomics
$35.12 /

-1.59 (-4.33%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.